Needham & Company LLC Reaffirms “Buy” Rating for NextCure (NASDAQ:NXTC)

Needham & Company LLC reaffirmed their buy rating on shares of NextCure (NASDAQ:NXTC) in a research note released on Friday morning, Benzinga reports. Needham & Company LLC currently has a $4.00 price target on the stock.

Separately, HC Wainwright reaffirmed a buy rating and issued a $8.00 target price on shares of NextCure in a research report on Friday.

NextCure Price Performance

Shares of NASDAQ NXTC traded up $0.04 during mid-day trading on Friday, hitting $1.53. The company had a trading volume of 108,827 shares, compared to its average volume of 147,942. NextCure has a 12 month low of $0.98 and a 12 month high of $2.57. The firm has a market cap of $42.79 million, a P/E ratio of -0.67 and a beta of 0.54. The business’s 50-day simple moving average is $1.72 and its 200-day simple moving average is $1.40.

NextCure (NASDAQ:NXTC) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.02. As a group, sell-side analysts predict that NextCure will post -1.65 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Marquette Asset Management LLC bought a new stake in shares of NextCure in the 4th quarter valued at approximately $66,000. Acuitas Investments LLC lifted its position in shares of NextCure by 30.0% during the 4th quarter. Acuitas Investments LLC now owns 372,799 shares of the company’s stock worth $425,000 after buying an additional 85,982 shares during the period. Cable Car Capital LLC acquired a new stake in NextCure in the 4th quarter valued at $702,000. Finally, Assenagon Asset Management S.A. bought a new stake in NextCure in the first quarter valued at $952,000. Institutional investors and hedge funds own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.